Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report
Abstract A 76‐year‐old man underwent an operation for lung squamous cell carcinoma in the right lower lobe, followed by initial adjuvant therapy with atezolizumab, an antibody against anti‐programmed death‐ligand 1 (PD‐L1). On day 4 after atezolizumab treatment, the patient developed general malaise...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2024-03-01
|
| Series: | Respirology Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/rcr2.1324 |
| _version_ | 1797242771239600128 |
|---|---|
| author | Daisuke Jingu Akira Horii Takehiro Yajima Ryuta Ohira Satoshi Ubukata Kosuke Satou Hiroshi Takahashi Hiroshi Watanabe Hiroyuki Funayama |
| author_facet | Daisuke Jingu Akira Horii Takehiro Yajima Ryuta Ohira Satoshi Ubukata Kosuke Satou Hiroshi Takahashi Hiroshi Watanabe Hiroyuki Funayama |
| author_sort | Daisuke Jingu |
| collection | DOAJ |
| description | Abstract A 76‐year‐old man underwent an operation for lung squamous cell carcinoma in the right lower lobe, followed by initial adjuvant therapy with atezolizumab, an antibody against anti‐programmed death‐ligand 1 (PD‐L1). On day 4 after atezolizumab treatment, the patient developed general malaise and fatigue. He was diagnosed with atezolizumab‐induced sclerosing cholangitis. Steroid treatment was started, and patient's condition, including symptoms, laboratory data and imaging findings, improved. Antibiotic treatments were ended on day 40, and the steroid dose was gradually reduced. Multiple liver abscesses were observed on day 106, and another treatment with antibiotics became necessary. The patient eventually recovered from liver abscesses. Sclerosing cholangitis induced by immune checkpoint inhibitor is rare, and the long‐term clinical data about this adverse effect is limited. Hence, we think it is important to raise an alarm over sclerosing cholangitis coupled with liver abscesses after immunosuppressive therapy. |
| first_indexed | 2024-04-24T18:44:31Z |
| format | Article |
| id | doaj.art-ba2663efdeac402fa95accfe713046c3 |
| institution | Directory Open Access Journal |
| issn | 2051-3380 |
| language | English |
| last_indexed | 2024-04-24T18:44:31Z |
| publishDate | 2024-03-01 |
| publisher | Wiley |
| record_format | Article |
| series | Respirology Case Reports |
| spelling | doaj.art-ba2663efdeac402fa95accfe713046c32024-03-27T08:30:32ZengWileyRespirology Case Reports2051-33802024-03-01123n/an/a10.1002/rcr2.1324Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case reportDaisuke Jingu0Akira Horii1Takehiro Yajima2Ryuta Ohira3Satoshi Ubukata4Kosuke Satou5Hiroshi Takahashi6Hiroshi Watanabe7Hiroyuki Funayama8Department of Respiratory Medicine Saka General Hospital Shiogama JapanDepartment of Internal Medicine Saka General Hospital Shiogama JapanDepartment of Respiratory Medicine Saka General Hospital Shiogama JapanDepartment of Respiratory Medicine Saka General Hospital Shiogama JapanDepartment of Respiratory Medicine Saka General Hospital Shiogama JapanDepartment of Respiratory Medicine Saka General Hospital Shiogama JapanDepartment of Respiratory Medicine Saka General Hospital Shiogama JapanDepartment of Respiratory Medicine Saka General Hospital Shiogama JapanDepartment of Gastroenterology and Hepatology Saka General Hospital Shiogama JapanAbstract A 76‐year‐old man underwent an operation for lung squamous cell carcinoma in the right lower lobe, followed by initial adjuvant therapy with atezolizumab, an antibody against anti‐programmed death‐ligand 1 (PD‐L1). On day 4 after atezolizumab treatment, the patient developed general malaise and fatigue. He was diagnosed with atezolizumab‐induced sclerosing cholangitis. Steroid treatment was started, and patient's condition, including symptoms, laboratory data and imaging findings, improved. Antibiotic treatments were ended on day 40, and the steroid dose was gradually reduced. Multiple liver abscesses were observed on day 106, and another treatment with antibiotics became necessary. The patient eventually recovered from liver abscesses. Sclerosing cholangitis induced by immune checkpoint inhibitor is rare, and the long‐term clinical data about this adverse effect is limited. Hence, we think it is important to raise an alarm over sclerosing cholangitis coupled with liver abscesses after immunosuppressive therapy.https://doi.org/10.1002/rcr2.1324atezolizumabimmune checkpoint inhibitorimmune‐related adverse eventsliver abscesssclerosing cholangitis |
| spellingShingle | Daisuke Jingu Akira Horii Takehiro Yajima Ryuta Ohira Satoshi Ubukata Kosuke Satou Hiroshi Takahashi Hiroshi Watanabe Hiroyuki Funayama Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report Respirology Case Reports atezolizumab immune checkpoint inhibitor immune‐related adverse events liver abscess sclerosing cholangitis |
| title | Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report |
| title_full | Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report |
| title_fullStr | Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report |
| title_full_unstemmed | Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report |
| title_short | Atezolizumab‐related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma: A case report |
| title_sort | atezolizumab related sclerosing cholangitis with multiple liver abscesses in a patient with lung squamous cell carcinoma a case report |
| topic | atezolizumab immune checkpoint inhibitor immune‐related adverse events liver abscess sclerosing cholangitis |
| url | https://doi.org/10.1002/rcr2.1324 |
| work_keys_str_mv | AT daisukejingu atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT akirahorii atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT takehiroyajima atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT ryutaohira atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT satoshiubukata atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT kosukesatou atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT hiroshitakahashi atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT hiroshiwatanabe atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport AT hiroyukifunayama atezolizumabrelatedsclerosingcholangitiswithmultipleliverabscessesinapatientwithlungsquamouscellcarcinomaacasereport |